Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. STKE, 13 April 2004
Vol. 2004, Issue 228, p. tw135
[DOI: 10.1126/stke.2282004TW135]

EDITORS' CHOICE

CHANNELS Preventing Fatal Arrhythmias

The precise mechanisms that cause cardiac arrhythmias have been hard to pin down. Wehrens et al. describe the effects of the experimental drug JTV519, a derivative of 1,4-benzothiazepine, which causes increased binding of the protein calstabin2 to the ryanodine receptor. The ryanodine receptor is a calcium-release channel that contributes to muscle contraction. When calstabin binds, the channel is held in its closed state and calcium is not released. Mice that have decreased amounts of calstabin2 are prone to arrhythmias. Treatment with JTV519 protected such animals from fatal arrhythmias, but the drug had no effect on animals that completely lacked the calstabin2 protein. Thus, JTV519 appears to prevent arrhythmias by increasing association of calstabin with ryanodine-receptor channels, plugging the leak of calcium thought to initiate the life-threatening abnormal contractions.

X. H. T. Wehrens, S. E. Lehnart, S. R. Reiken, S.-X. Deng, J. A. Vest, D. Cervantes, J. Coromilas, D. W. Landry, A. R. Marks, Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304, 292-296 (2004). [Abstract] [Full Text]

Citation: Preventing Fatal Arrhythmias. Sci. STKE 2004, tw135 (2004).


To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882